NPM1 and acute lymphoblastic leukemia: DS-1594 has demonstrated high antileukemic activity in preclinical studies and is being clinically evaluated in R/R NPM1 or KMT2A AML and ALL in combination with chemotherapy—mini-HCVD, VEN, or AZA.